Hemispherx (HEB) Continuing Higher as Japanese Researchers Call Ampligen(r) 'Most Promising' Candidate for Flu Vaccines
Tweet Send to a Friend
Shares of the momentous Hemispherx BioPharma (AMEX: HEB) are adding another 16% onto recent gains today following news earlier that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
